Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: SelG1
DRUG: Placebo

Sponsor

Reprixys Pharmaceutical Corporation

Collaborators

[object Object]
[object Object]